Dose reductions of vincristine in children with medulloblastoma treated in the maintenance arm of the prospective multicenter trial HIT'91.

AuthorsA O von Bueren, K von Hoff, M Benesch, S Rutkowski
JournalKlinische Pàˆdiatrie (Klin Padiatr) 2009 Nov-Dec Vol. 221 Issue 6 Pg. 396-7 ISSN: 1439-3824 [Electronic] Germany
PMID19890797 (Publication Type: Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Antineoplastic Agents, Phytogenic
  • Vincristine
  • Lomustine
  • Cisplatin
  • Adolescent
  • Age Factors
  • Antineoplastic Agents, Phytogenic (administration & dosage, toxicity)
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use, toxicity)
  • Cerebellar Neoplasms (drug therapy, mortality, radiotherapy)
  • Child
  • Child, Preschool
  • Cisplatin (administration & dosage, toxicity)
  • Combined Modality Therapy
  • Disease-Free Survival
  • Dose-Response Relationship, Drug
  • Female
  • Humans
  • Lomustine (administration & dosage, toxicity)
  • Male
  • Medulloblastoma (drug therapy, mortality, radiotherapy)
  • Neoadjuvant Therapy
  • Nervous System Diseases (chemically induced, prevention & control)
  • Prospective Studies
  • Radiotherapy, Adjuvant
  • Risk Factors
  • Vincristine (administration & dosage, toxicity)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: